-
目前,早期非小细胞肺癌(non-small cell lung cancer,NSCLC)标准的治疗手段是手术治疗[1],但对于无法耐受手术或拒绝手术的患者,可采用125I放射性粒子近距离治疗,其作为一种精确的内放疗技术,治疗后患者的不良反应较小,1年的局控率达90%[2]。该治疗已受到越来越多医师及患者的青睐,但该方法给患者带来的肺损伤并未引起重视。在本研究中,我们对58例应用CT引导下经皮穿刺植入放射性125I粒子治疗的早期NSCLC患者进行了研究,根据是否合并慢性阻塞性肺疾病(chronic obstructive pulmonary disease,COPD)进行分组,观察治疗前后肺功能的变化情况。
-
D90为(114.3±10.2) Gy,90%剂量覆盖的靶体积百分比(V90)为(92.3±7.2)%,术后验证MPD的中位值为112.8 Gy。
-
不合并COPD组与合并COPD组患者治疗前后的FVC%比较,差异无统计学意义(t=0.70、0.20,均P>0.05)。合并COPD组治疗前后DLCO之间的差异无统计学意义(t=1.11,P=0.563),但不合并COPD组治疗前后的DLCO之间的差异有统计学意义(t=2.29,P=0.019)(表1、表2)。
检测项目 植入前 植入后 t值 P值 FEV1(L) 2.00±0.62 2.00±0.48 0.01 0.894 FEV1% 81.00±28.00 83.00±32.00 0.30 0.782 FVC(L) 3.00±0.47 3.00±0.65 0.01 0.912 FVC% 88.00±20.70 91.00±18.80 0.70 0.832 DLCO 11.00±6.40 14.00±5.60 2.29 0.019 DLCO% 61.00±18.00 69.00±20.00 2.62 0.021 注:表中,COPD:慢性阻塞性肺疾病;FEV1:一秒用力呼气容积;FVC:用力肺活量;DLCO:肺一氧化碳弥散量。 表 1 42例不合并COPD患者125I粒子植入前后肺功能检查的结果
Table 1. Result of pulmonary function tests before and after implantation of 125I seeds in 42 patients with COPD
检测项目 植入前 植入后 t值 P值 FEV1(L) 1.00±0.17 1.00±0.28 0.01 0.764 FEV1% 40.00±8.30 41.00±6.90 0.37 0.421 FVC(L) 2.00±0.30 2.00±0.40 0.01 0.683 FVC% 61.00±15.00 60.00±13.00 0.20 0.615 DLCO 12.00±3.00 13.00±2.00 1.11 0.563 DLCO% 48.00±11.00 49.00±12.00 0.25 0.652 注:表中,COPD:慢性阻塞性肺疾病;FEV1:一秒用力呼气容积;FVC:用力肺活量;DLCO:肺一氧化碳弥散量。 表 2 16例合并COPD患者125I粒子植入前后肺功能检查的结果
Table 2. Result of pulmonary function tests before and after implantation of 125I seeds in 16 patients with COPD
由表3可见,在粒子植入治疗前后,合并COPD组、不合并COPD组肿瘤体积的比较差异均无统计学意义(t=1.82、1.26,均P>0.05),但合并COPD组和不合并COPD组在粒子植入前后肿瘤体积之间的差异均有统计学意义(t=5.78、9.96,均P<0.001)。
患者 肿瘤体积(mm3) t值 P值 例数 植入前 植入后 合并COPD 16 18±7 7±3 5.78 <0.001 不合并COPD 42 21±5 9±6 9.96 <0.001 t值 1.82 1.26 P值 0.568 0.735 注:表中,COPD:慢性阻塞性肺疾病。 表 3 2组非小细胞肺癌患者125I粒子植入前后肿瘤体积变化情况
Table 3. Changes in tumor volume before and after implantation of 125I seeds in two groups of non-small cell lung cancer patients
根据术后质量验证MPD大小可知,>110 Gy组共有患者34例,≤110 Gy组共有患者24例,合并COPD组和不合并COPD组的FEV1%之间和FVC%之间的差异均无统计学意义(t=0.54、0.37、0.21、0.22,均P>0.05)(表4)。
分组 病例数 FEV1% FVC% >110 Gy组 合并COPD 10 41.0±7.6 60.0±11.0 不合并COPD 24 82.0±20.0 90.0±16.5 ≤110 Gy组 合并COPD 24 40.0±5.8 61.0±9.0 不合并COPD 6 83.0±15.0 91.0±18.3 注:表中,MPD:匹配周边剂量;COPD:慢性阻塞性肺疾病;FEV1:一秒用力呼气容积;FVC:用力肺活量。 表 4 根据125I粒子植入后质量验证MPD分组比较两组非小细胞肺癌患者肺功能情况
Table 4. Comparison of lung function in the two groups according to 125I post-implantation quality verification MPD
根据术后质量验证D90大小可知,>110 Gy组共有34例患者,≤110 Gy组共有24例患者,合并COPD组的FEV1%之间(t=0.56,P>0.05)和FVC%之间(t=0.29,P>0.05)与不合并COPD组的FEV1%之间(t=0.30,P>0.05)和FVC%之间(t=0.24,P>0.05)的差异均无统计学意义。
125I放射性粒子植入治疗对不能或不愿手术的早期非小细胞肺癌患者肺功能的影响
Effect of 125I implantation on pulmonary function in impossible non-small cell lung cancer
-
摘要:
目的 评估CT引导下植入125I放射性粒子治疗早期(IA、IB期)非小细胞肺癌(NSCLC)后对患者肺功能的影响。 方法 选取2013年10月至2018年6月接受125I放射性粒子植入治疗的早期NSCLC患者58例,根据治疗前的肺功能检测结果将患者分为合并慢性阻塞性肺疾病(COPD)组16例(男性10例、女性6例)和不合并COPD组42例(男性28例、女性14例),术后2~6个月检测肺功能指标,包括第一秒用力呼气容积(FEV1)、用力肺活量(FVC)、肺一氧化碳弥散量(DLCO)变化的情况。组间比较采用t检验。 结果 覆盖90%靶体积时的剂量(D90)为(114.3±10.2)Gy,90%剂量覆盖的靶体积百分比(V90)为(92.3±7.2)%,术后验证匹配周边剂量(MPD)的中位值为112.8 Gy。随访6个月,不合并COPD组与合并COPD组患者治疗前后的 FVC%差异均无统计学意义(t=0.70、0.20,均P>0.05)。合并COPD组治疗前后的DLCO之间的差异无统计学意义(t=1.11,P=0.563),但不合并COPD组治疗前后的DLCO之间的差异有统计学意义(t=2.29,P=0.019)。治疗前后,合并COPD组和不合并COPD组肿瘤体积之间的差异均无统计学意义(t=1.82、1.26,均P>0.05),但合并COPD组和不合并COPD组在治疗前后肿瘤体积之间的差异均有统计学意义(t=5.78、9.96,均P<0.001)。根据术后质量验证MPD和D90大小分为2组(>110 Gy组和≤110 Gy组),合并COPD组和不合并COPD组的FEV1%之间、FVC%之间的差异均无统计学意义(t=0.54、0.37、0.21、0.22,均P>0.05)。 结论 125I放射性粒子植入治疗早期NSCLC对患者FEV1%和FVC%无明显影响,但能够改善不合并COPD且肿瘤明显缩小患者的肺功能。 Abstract:Objective To evaluate pulmonary function and tumor volume before and after CT-guided radioactive 125I seed implantation in inoperable patients with and without chronic obstructive pulmonary disease(COPD) in early-stage(IA, IB) lung cancer. Methods From October 2013 to June 2018, 58 patients with early non-small cell lung cancer were treated with 125I radioactive seed implantation. Patients were divided according to the results of pre-treatment pulmonary function tests: 16 patients(10 males and 6 females) were included in the COPD groups and 42 patients(28 males and 14 females) were included in the No-COPD group. Changes in pulmonary function forced expiratory volume in one second, diffusing capacity of the lungs for carbon monoxide(DLCO), and forced vital capacity were detected within 2–6 months after operation. Statistical analysis was conducted via t test. Results The D90 was(114.3±10.2) Gy, the V90 was(92.3±7.2)%, and the matched peripheral dose was 112.8 Gy. The pretreatment and post treatment FEV% of the COPD and No-COPD groups were similar at a mean follow-up time of 6 months(t =0.70, 0.20, both P>0.05). The DLCO of the COPD group did not change after CT-guided radioactive 125I seed implantation treatment(t=1.11, P=0.563); however, DLCO significantly increased in the No-COPD group(t=2.29, P=0.019). There was no significant difference in the tumor volume between the COPD group and the No-COPD group before and after treatment(t=1.82, 1.26, both P>0.05), but the difference between the COPD group and the tumor volume of the No-COPD group was statistically significant before and after the treatment(t=5.78, 9.96, both P<0.001). According to postoperative quality validation of MPD and D90, all the patients were divided into > 110 Gy group(34 cases) and ≤110 Gy group(24 cases), differences in the FEV1% and FVC% of the COPD and No-COPD groups after implantation were not statistically significant(t=0.54, 0.37, 0.21, 0.22, all P>0.05). Conclusion 125I implantation therapy for inoperable non-small cell lung cancer does not seem to affect FEV1% and FVC% but can shrink tumor volume and improve DLCO in patients without COPD -
表 1 42例不合并COPD患者125I粒子植入前后肺功能检查的结果
Table 1. Result of pulmonary function tests before and after implantation of 125I seeds in 42 patients with COPD
检测项目 植入前 植入后 t值 P值 FEV1(L) 2.00±0.62 2.00±0.48 0.01 0.894 FEV1% 81.00±28.00 83.00±32.00 0.30 0.782 FVC(L) 3.00±0.47 3.00±0.65 0.01 0.912 FVC% 88.00±20.70 91.00±18.80 0.70 0.832 DLCO 11.00±6.40 14.00±5.60 2.29 0.019 DLCO% 61.00±18.00 69.00±20.00 2.62 0.021 注:表中,COPD:慢性阻塞性肺疾病;FEV1:一秒用力呼气容积;FVC:用力肺活量;DLCO:肺一氧化碳弥散量。 表 2 16例合并COPD患者125I粒子植入前后肺功能检查的结果
Table 2. Result of pulmonary function tests before and after implantation of 125I seeds in 16 patients with COPD
检测项目 植入前 植入后 t值 P值 FEV1(L) 1.00±0.17 1.00±0.28 0.01 0.764 FEV1% 40.00±8.30 41.00±6.90 0.37 0.421 FVC(L) 2.00±0.30 2.00±0.40 0.01 0.683 FVC% 61.00±15.00 60.00±13.00 0.20 0.615 DLCO 12.00±3.00 13.00±2.00 1.11 0.563 DLCO% 48.00±11.00 49.00±12.00 0.25 0.652 注:表中,COPD:慢性阻塞性肺疾病;FEV1:一秒用力呼气容积;FVC:用力肺活量;DLCO:肺一氧化碳弥散量。 表 3 2组非小细胞肺癌患者125I粒子植入前后肿瘤体积变化情况
Table 3. Changes in tumor volume before and after implantation of 125I seeds in two groups of non-small cell lung cancer patients
患者 肿瘤体积(mm3) t值 P值 例数 植入前 植入后 合并COPD 16 18±7 7±3 5.78 <0.001 不合并COPD 42 21±5 9±6 9.96 <0.001 t值 1.82 1.26 P值 0.568 0.735 注:表中,COPD:慢性阻塞性肺疾病。 表 4 根据125I粒子植入后质量验证MPD分组比较两组非小细胞肺癌患者肺功能情况
Table 4. Comparison of lung function in the two groups according to 125I post-implantation quality verification MPD
分组 病例数 FEV1% FVC% >110 Gy组 合并COPD 10 41.0±7.6 60.0±11.0 不合并COPD 24 82.0±20.0 90.0±16.5 ≤110 Gy组 合并COPD 24 40.0±5.8 61.0±9.0 不合并COPD 6 83.0±15.0 91.0±18.3 注:表中,MPD:匹配周边剂量;COPD:慢性阻塞性肺疾病;FEV1:一秒用力呼气容积;FVC:用力肺活量。 -
[1] Jia B, Zheng QW, Qi XM, et al. Survival comparison of right and left side non-small cell lung cancer in stage I-IIIA patients: A Surveillance Epidemiology and End Results (SEER) analysis[J]. Thorac Cancer, 2019, 10(3): 459−471. DOI: 10.1111/1759−7714.12959. [2] 杨景魁, 霍小东, 闫卫亮, 等. CT引导下经皮穿刺125I粒子植入治疗非手术的早期非小细胞肺癌疗效分析[J]. 中华老年医学杂志, 2014, 33(7): 757−759. DOI: 10.3760/cma.j.issn.0254−9026.2014.07.018.
Yang JK, Huo XD, Yan WL, et al. Effect of CT-guided 125I seeds implant brachytherapy on early non-small cell lung cancer[J]. Chin J Geriatr, 2014, 33(7): 757−759. DOI: 10.3760/cma.j.issn.0254−9026.2014.07.018.[3] 中华医学会呼吸病学分会慢性阻塞性肺疾病学组. 慢性阻塞性肺疾病诊治指南(2013年修订版)[J]. 中华结核和呼吸杂志, 2013, 36(4): 1−10. DOI: 10.3760/cma.j.issn.1001−0939.2013.04.000.
Chronic Obstructive Pulmonary Disease Group, Society of Respiratory Diseases, Chinese Medical Association. Diagnosis and treatment guidelines of chronic obstructive pulmonary disease (2013 revised edition)[J]. Chin J Tuberc Respir Dis, 2013, 36(4): 1−10. DOI: 10.3760/cma.j.issn.1001−0939.2013.04.000.[4] Lemjabbar-Alaoui H, Hassan OU, Yang YW, et al. Lung cancer: biology and treatment options[J]. Biochim Biophys Acta, 2015, 1856(2): 189−210. DOI: 10.1016/j.bbcan.2015.08.002. [5] Logghe P, Verlinde R, Bouttens F, et al. Long term outcome and side effects in patients receiving low-dose I125 brachytherapy: a retrospective analysis[J]. Int Braz J Urol, 2016, 42(5): 906−917. DOI: 10.1590/S1677−5538.IBJU.2015.0542. [6] Li JK, Yu M, Xiao YY, et al. Computed tomography fluoroscopy-guided percutaneous 125I seed implantation for safe, effective and real-time monitoring radiotherapy of inoperable stage T1-3N0M0 non-small-cell lung cancer[J]. Mol Clin Oncol, 2013, 1(6): 1019−1024. DOI: 10.3892/mco.2013.171. [7] 霍小东, 郑广钧, 柴树德, 等. CT引导下125I放射性粒子植入治疗Ⅲ期非小细胞肺癌疗效分析[J]. 中华放射医学与防护杂志, 2012, 32(2): 199−203. DOI: 10.3760/cma.j.issn.0254−5098.2012.02.023.
Huo XD, Zheng GJ, Chai SD, et al. Clinical efficacy of CT-guided 125I radioactive seeds implantation for stage Ⅲ of non-small cell lung cancer[J]. Chin J Radiol Med Prot, 2012, 32(2): 199−203. DOI: 10.3760/cma.j.issn.0254−5098.2012.02.023.[8] Huo XD, Huo B, Wang HX, et al. Percutaneous computed tomography-guided permanent 125I implantation as therapy for pulmonary metastasis[J]. J Contemp Brachytherapy, 2018, 100(2): 132−141. DOI: 10.5114/jcb.2018.75598. [9] Bishawi M, Kim B, Moore WH, et al. Pulmonary Function Testing After Stereotactic Body Radiotherapy to the Lung[J]. Int J Radiat Oncol Biol Phys, 2012, 82(1): e107−e110. DOI: 10.1016/j.ijrobp.2011.01.037. [10] Henderson M, McGarry R, Yiannoutsos C, et al. Baseline Pulmonary Function as a Predictor for Survival and Decline in Pulmonary Function Over Time in Patients Undergoing Stereotactic Body Radiotherapy for the Treatment of Stage I Non-Small-Cell Lung Cancer[J]. Int J Radiat Oncol Biol Phys, 2008, 72(2): 404−409. DOI: 10.1016/j.ijrobp.2007.12.051. [11] Niezink AGH, de Jong RA, Muijs CT, et al. Pulmonary Function Changes After Radiotherapy for Lung or Esophageal Cancer: A Systematic Review Focusing on Dose-Volume Parameters[J]. Oncologist, 2017, 22(10): 1257−1264. DOI: 10.1634/theoncologist.2016−0324.